Holen Sie sich die Stockscreener-App
4.53
0.88%
-0.04
Handel nachbörslich:
4.45
-0.08
-1.77%
Schlusskurs vom Vortag:
$4.57
Offen:
$4.58
24-Stunden-Volumen:
3.54M
Relative Volume:
1.05
Marktkapitalisierung:
$609.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-217.44M
KGV:
-2.0876
EPS:
-2.17
Netto-Cashflow:
$-205.20M
1W Leistung:
+5.59%
1M Leistung:
+118.84%
6M Leistung:
+42.45%
1J Leistung:
-16.42%
1-Tages-Spanne:
$4.435
$4.6888
1-Wochen-Bereich:
$3.71
$5.17
52-Wochen-Spanne:
$1.11
$5.9499
Prime Medicine Inc Stock (PRME) Company Profile
Firmenname
Prime Medicine Inc
Sektor
Branche
Telefon
617-465-0013
Adresse
60 FIRST ST., CAMBRIDGE
Vergleichen Sie PRME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
4.53 | 576.99M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-04-08 | Eingeleitet | TD Cowen | Buy |
| 2024-04-03 | Eingeleitet | Wedbush | Outperform |
| 2024-01-16 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Eingeleitet | Citigroup | Neutral |
| 2023-10-09 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-07-31 | Eingeleitet | Guggenheim | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2022-11-14 | Eingeleitet | Goldman | Neutral |
| 2022-11-14 | Eingeleitet | JP Morgan | Overweight |
| 2022-11-14 | Eingeleitet | Jefferies | Buy |
| 2022-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prime Medicine Inc Aktie (PRME) Neueste Nachrichten
Prime Medicine Inc. Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com
Is Prime Medicine Inc. a good long term investmentPowerful market insights - jammulinksnews.com
What drives Prime Medicine Inc. stock priceExponential wealth increase - Autocar Professional
What analysts say about Prime Medicine Inc. stockStrong return on assets - Autocar Professional
Prime Medicine(PRME) Shares Soar 10.65% on Analyst Rating, Funding Boost - AInvest
Prime Medicine Surges 18% on Funding Catalyst: Is This the Start of a Biotech Breakout? - AInvest
BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT - MSN
Prime Medicine stock price target reiterated at $6 by JMP on CF funding - Investing.com Canada
Prime Medicine (PRME.O) Surges 5.9%: What’s Behind the Intraday Rally? - AInvest
Prime Medicine (PRME): A High-Conviction Biotech Play with a 154% Upside - AInvest
10 Hot Penny Stocks to Invest in Now - Insider Monkey
Cystic Fibrosis Foundation grants new funding to advance development of Prime Medicine’s prime editors - BioWorld MedTech
Prime Medicine, Inc.: Buy Rating Affirmed on Innovative Gene Editing Technology and Strategic Advancements - TipRanks
Prime Medicine stock rating reiterated by H.C. Wainwright on CF partnership - Investing.com Canada
CF Trading Volume Surges 77% to 2.91 Billion, Ranks 364th in Market - AInvest
Prime Editing's Billion-Dollar Gamble: Can Prime Medicine's $24M Boost Cement Dominance in Cystic Fibrosis? - AInvest
Prime Medicine announces additional funding of up to $24M from CF Foundation - TipRanks
Prime Medicine Announces Additional Funding of Up to $24 - GlobeNewswire
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation - citybiz
Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy - Yahoo Finance
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis - The Manila Times
Cystic Fibrosis Foundation expands funding for Prime Medicine By Investing.com - Investing.com Nigeria
Cystic Fibrosis Foundation expands funding for Prime Medicine - Investing.com
CF Foundation Backs Prime Medicine with $24M to Develop Cure for 93% of Cystic Fibrosis Patients - Stock Titan
Prime Medicine chief scientific officer to depart, will serve as consultant - Investing.com Nigeria
Prime Medicine Announces CSO Resignation and Transition - TipRanks
Prime Medicine stock plummets amid restructuring and leadership changes - MSN
Prime Medicine soars as Jones sees it as an acquisition target - MSN
Prime Medicine's Liver Gene Therapy Platform: A Breakthrough in Rare Disease Treatment? - AInvest
Prime Medicine: Pressing Forward With Lead Liver Targeting Indications (NASDAQ:PRME) - Seeking Alpha
Prime Therapeutics stock surges 35% on JonesTrading's acquisition optimism. - AInvest
JonesResearch lists factors for Prime Medicine continued share rally - TipRanks
Prime Medicine stock soars amid gene editing sector momentum By Investing.com - Investing.com Canada
Prime Medicine, Inc.: Buy Rating Driven by Strategic Positioning and Market Momentum - TipRanks
Prime Medicine's Liver Pivot: A Billion-Dollar Leap with Validated Prime Editing - AInvest
Finanzdaten der Prime Medicine Inc-Aktie (PRME)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):